Equities

Sareum Holdings PLC

SAR:LSE

Sareum Holdings PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)26.50
  • Today's Change0.50 / 1.92%
  • Shares traded137.95k
  • 1 Year change-57.60%
  • Beta-0.7161
Data delayed at least 20 minutes, as of Nov 22 2024 16:04 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Sareum Holdings plc is a United Kingdom-based biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's internal programs focus on distinct dual tyrosine kinase 2 (TYK2)/ Janus kinase 1 (JAK1) inhibitors, which are progressing through preclinical development as therapies for autoimmune diseases and cancers. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. It is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. The Company also has an interest in SRA737, an orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and a central mediator of the DNA damage response (DDR) network.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-3.42m
  • Incorporated2004
  • Employees5.00
  • Location
    Sareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
  • Phone+44 12 2349 7700Fax+44 12 2349 7701
  • Websitehttps://sareum.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
ImmuPharma PLC-69.96k-2.46m6.54m5.006.54m5.00
LungLife AI Inc23.04k-3.55m7.32m15.007.32m15.00
Cizzle Biotechnology Holdings PLC0.00-2.70m7.53m67.007.53m67.00
Synairgen plc0.00-6.92m9.38m36.009.38m36.00
IXICO PLC6.00m-1.87m11.12m89.0011.12m89.00
OptiBiotix Health PLC569.00k-2.98m12.00m5.0012.00m5.00
Incanthera PLC0.00-1.55m16.37m7.0016.37m7.00
Hemogenyx Pharmaceuticals PLC0.00-5.18m21.38m17.0021.38m17.00
Shield Therapeutics PLC20.88m-36.17m23.07m73.0023.07m73.00
Arecor Therapeutics PLC4.90m-8.67m28.88m50.0028.88m50.00
Sareum Holdings Plc0.00-3.42m32.43m5.0032.43m5.00
Skinbiotherapeutics PLC161.65k-2.88m36.26m11.0036.26m11.00
Poolbeg Pharma PLC0.00-4.38m38.00m8.0038.00m8.00
Data as of Nov 22 2024. Currency figures normalised to Sareum Holdings PLC's reporting currency: UK Pound GBX

Institutional shareholders

11.77%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Asset Management Ltd.as of 01 Jul 20247.37m5.91%
HSBC Global Asset Management (UK) Ltd.as of 01 Jul 20244.66m3.74%
IG Markets Ltd.as of 01 Jul 2024649.00k0.52%
Jarvis Investment Management Ltd.as of 01 Jul 2024497.00k0.40%
KW Investment Management Ltd.as of 01 Jul 2024478.00k0.38%
HSBC Bank Plc (Market-Maker)as of 01 Jul 2024287.00k0.23%
Evelyn Partners Investment Management Services Ltd.as of 01 Jul 2024228.00k0.18%
Rowan Dartington & Co. Ltd. (Broker)as of 01 Jul 2024184.00k0.15%
Rathbones Investment Management Ltd.as of 01 Jul 2024179.00k0.14%
Eurizon Capital SGR SpAas of 01 Jul 2024152.00k0.12%
More ▼
Data from 31 Dec 2023 - 05 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.